Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMIBH7M)

Drug Name
L-Tryptophan Drug Info
Synonyms
Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine
Therapeutic ClassAntidepressants
Cross-matching ID
PubChem CID
6305
ChEBI ID
CHEMBL54976
CAS Number
CAS 73-22-3
TTD Drug ID
D05EJG
VARIDT Drug ID
DR00086
INTEDE Drug ID
DR0991

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Phosphatidylinositol signaling system 2.05 0.00e+0 82/97 (84.54%) PRKCA;PLCB1;INPP4B;...
Inositol phosphate metabolism 1.91 1.64e-2 66/73 (90.41%) PLCB1;INPP4B;INPP5F;...
Amoebiasis 1.84 3.29e-2 99/102 (97.06%) LAMB1;PRKCA;PLCB1;...
Wnt signaling pathway 1.81 2.74e-2 124/166 (74.7%) SFRP1;PRKCA;PLCB1;...
Regulation of lipolysis in adipocytes 1.81 2.19e-2 52/55 (94.55%) FABP4;GNAS;IRS1;...
Notch signaling pathway 1.78 2.56e-2 49/59 (83.05%) TLE4;NOTCH2;PSEN1;...
Cortisol synthesis and secretion 1.78 2.82e-2 58/65 (89.23%) PLCB1;GNAS;PBX1;...
Aldosterone synthesis and secretion 1.77 2.74e-2 85/98 (86.73%) PRKCA;PLCB1;ATP1B3;...
Aldosterone-regulated sodium reabsorption 1.77 2.43e-2 34/37 (91.89%) PRKCA;ATP1B3;IRS1;...
Pancreatic secretion 1.75 2.85e-2 87/102 (85.29%) PRKCA;PLCB1;ATP1B3;...
Thyroid hormone signaling pathway 1.72 3.78e-2 112/121 (92.56%) PRKCA;PLCB1;ATP1B3;...
Galactose metabolism 1.71 3.47e-2 26/31 (83.87%) AKR1B10;SI;AKR1B1;...
Renin secretion 1.70 3.37e-2 61/69 (88.41%) PLCB1;GNAS;ADRB2;...
AMPK signaling pathway 1.70 3.60e-2 106/120 (88.33%) CD36;IRS1;ADIPOQ;...
Focal adhesion 1.68 3.94e-2 180/201 (89.55%) LAMB1;PRKCA;COL4A5;...
Biosynthesis of unsaturated fatty acids 1.67 4.31e-2 21/27 (77.78%) HSD17B4;ELOVL6;FADS1;...
Insulin resistance 1.66 4.32e-2 96/108 (88.89%) CD36;IRS1;CPT1A;...
Insulin signaling pathway 1.66 4.26e-2 121/137 (88.32%) SORBS1;IRS1;ACACA;...
Gap junction 1.66 4.09e-2 72/88 (81.82%) PRKCA;PLCB1;PDGFC;...
Cushing syndrome 1.66 3.94e-2 125/155 (80.65%) PLCB1;CDKN1B;GNAS;...
Melanogenesis 1.66 3.76e-2 74/101 (73.27%) PRKCA;PLCB1;GNAS;...
Sulfur metabolism 1.66 3.68e-2 9/10 (90%) TST;SQOR;MPST;...
Glucagon signaling pathway 1.66 3.52e-2 89/107 (83.18%) PLCB1;GNAS;ACACA;...
Cell cycle 1.65 3.83e-2 110/124 (88.71%) CDKN1B;CDC20;PCNA;...
Natural killer cell mediated cytotoxicity -1.69 3.50e-2 99/131 (75.57%) KLRC3;HLA-E;FAS;...
Parkinson disease -1.69 3.82e-2 176/249 (70.68%) KIF5A;ATP5F1D;PSMD8;...
Prion disease -1.77 1.61e-2 209/273 (76.56%) NDUFS7;PSMC1;STIP1;...
Toll-like receptor signaling pathway -1.80 1.19e-2 94/104 (90.38%) MAPK10;MAP2K6;TLR5;...
Type I diabetes mellitus -1.81 1.23e-2 38/43 (88.37%) HLA-E;PTPRN;FAS;...
Staphylococcus aureus infection -1.87 3.83e-3 72/95 (75.79%) FPR2;C1S;C2;...
Cytokine-cytokine receptor interaction -2.03 1.49e-3 246/295 (83.39%) IL4R;CCL16;FAS;...
Proteasome -2.07 0.00e+0 44/46 (95.65%) PSMD8;PSME3;PSMA2;...
Antigen processing and presentation -2.08 0.00e+0 60/78 (76.92%) NFYB;KLRC3;HLA-E;...
Ribosome -2.11 0.00e+0 113/158 (71.52%) RPL37;RPS20;MRPS14;...
Viral protein interaction with cytokine and cytokine re... -2.15 0.00e+0 84/100 (84%) CXCR2;CXCR1;CCL2;...
Oxidative phosphorylation -2.20 0.00e+0 93/133 (69.92%) ATP6V0C;ATP5F1D;NDUFV1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 20uM 6H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 12uM - 100uM 48H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 20uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.08uM - 100uM 3H, 24H, 48H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.08uM - 20uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 20uM 6H, 24H